Back
Corporate News
Auro Vaccines terminates license agreement with Hilleman Laboratories Singapore
05-Mar-2025, 11:25
Auro Vaccines, a wholly owned step-down subsidiary of Aurobindo Pharma, has today, 05 March 2025, terminated the License Agreement (entered on 27 September 2023) with Hilleman Laboratories Singapore to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.
Auro Vaccines, a wholly owned step-down subsidiary of Aurobindo Pharma, has today, 05 March 2025, terminated the License Agreement (entered on 27 September 2023) with Hilleman Laboratories Singapore to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.
Powered by Capital Market - Live News